Investigation of maternal serum hepassocin concentrations in pregnant women with gestational diabetes mellitus: a prospective case-control study

Abstract

Objective We aimed to investigate the relationship between gestational diabetes mellitus (GDM) and maternal serum hepassocin concentrations.

Materials and methods This cross-sectional study was conducted with 88 pregnant women who applied to the Ümraniye Training and Research Hospital Gynecology and Obstetrics Clinic between April 2022 and November 2022. The GDM group consisted of 44 pregnant women who had a 75-g OGTT between the 24th and 28th week of pregnancy and were diagnosed with GDM. The control group consisted of 44 healthy pregnant women who were matched with the GDM group in terms of age and body mass index (BMI) and had a normal 75-g OGTT result. Demographic characteristics, laboratory findings, and perinatal outcomes were noted. Two groups were compared in terms of maternal serum hepassocin concentrations.

Results Both groups were similar in terms of age, BMI, weight gain, gravida, parity, polycystic ovary syndrome history, history of diabetes mellitus in the family, and the gestational week at blood sampling for hepassocin (p>0.05 for each). The median maternal serum hepassocin concentration was found to be 18.21 ng/ml in the GDM group, while it was determined as 13.05 ng/ml in the non-GDM group (p=0.012). The GDM group was divided into two groups: the group that only dieted until birth and the group that used insulin until birth for blood glucose regulation. The median hepassocin concentration was found to be 17.99 ng/ml in the diet-only GDM group and 32.15 ng/ml in the insulin-using GDM group. ROC analysis was performed to determine the value of maternal serum hepassocin concentration in predicting GDM. AUC analysis of maternal serum hepassocin for estimation of GDM was 0.656 (p=0.012, 95% CI=0.53–0.77). The optimal threshold value for maternal serum hepassocin concentration was determined as 14.13 ng/ml with 61.4% sensitivity and 61.4% specificity.

Conclusion Serum hepassocin concentration evaluated between 24 and 28 weeks of gestation was found to be higher in pregnant women with GDM than in the non-GDM group. The highest serum hepassocin concentration was found in the GDM group using insulin for blood glucose regulation. Hepassocin seems to be a promising molecule that can be used in GDM screening in pregnant women who do not want to have an OGTT in the future.

Key words

diabetes mellitus - gestational diabetes mellitus - hepassocin - impaired glucose tolerance - oral glucose tolerance test

Publikationsverlauf

Eingereicht: 04. Januar 2023

Angenommen nach Revision: 03. Mai 2023

Artikel online veröffentlicht:
27. Juni 2023

• References

• 1 ACOG Practice Bulletin. No. 190: Gestational Diabetes Mellitus. Obstet Gynecol 2018; 131: e49-e64 DOI: 10.1097/AOG.0000000000002501.
• 2 O’sullivan JB, Mahan CM.. Crıterıa for the oral glucose tolerance test ın pregnancy. Diabetes 1964; 13: 278-285
• 3 Lende M, Rijhsinghani A.. Gestational diabetes: Overview with emphasis on medical management. Int J Environ Res Public Health 2020; 17: 9573 DOI: 10.3390/ijerph17249573.
• 4 Magliano DJ, Boyko EJ. IDF Diabetes Atlas 10th Edition Committee. IDF Dıabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021
• 5 Sweeting A, Wong J, Murphy HR. et al. A clinical update on gestational diabetes mellitus. Endocr Rev 2022; 43: 763-793 DOI: 10.1210/endrev/bnac003.
• 6 Sert UY, Ozgu-Erdinc AS.. Gestational Diabetes Mellitus Screening and Diagnosis. In: Islam MdS, ed. Diabetes: from Research to Clinical Practice. Cham: Springer International Publishing; 2020: 231-255
• 7 Hartling L, Dryden DM, Guthrie A. et al. Screening and diagnosing gestational diabetes mellitus. Evid Rep Technol Assess 2012; 1-327
• 8 Karaçam Z, Çelİk D.. The prevalence and risk factors of gestational diabetes mellitus in Turkey: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2021; 34: 1331-1341 DOI: 10.1080/14767058.2019.1635109.
• 9 Ye W, Luo C, Huang J. et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2022; e067946 DOI: 10.1136/bmj-2021-067946.
• 10 Rottenstreich A, Elazary R, Ezra Y. et al. Hypoglycemia during oral glucose tolerance test among post–bariatric surgery pregnant patients: incidence and perinatal significance. Surg Obes Relat Dis 2018; 14: 347-353 DOI: 10.1016/j.soard.2017.11.031.
• 11 Andrade HF, de A, Pedrosa W, Diniz M, de FHS. et al. Adverse effects during the oral glucose tolerance test in post-bariatric surgery patients. Arch Endocrinol Metab 2016; 60: 307-313 DOI: 10.1590/2359-3997000000149.
• 12 Hara H, Uchida S, Yoshimura H. et al. Isolation and characterization of a novel liver-specific gene, hepassocin, upregulated during liver regeneration. Biochim Biophys Acta BBA – Gene Struct Expr 2000; 1492: 31-44 DOI: 10.1016/S0167-4781(00)00056-7.
• 13 Hara H, Yoshimura H, Uchida S. et al. Molecular cloning and functional expression analysis of a cDNA for human hepassocin, a liver-specific protein with hepatocyte mitogenic activity. Biochim Biophys Acta BBA – Gene Struct Expr 2001; 1520: 45-53 DOI: 10.1016/S0167-4781(01)00249-4.
• 14 Wu H-T, Lu F-H, Ou H-Y. et al. The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol 2013; 59: 1065-1072 DOI: 10.1016/j.jhep.2013.06.004.
• 15 Lu F-H, Ou H-Y, Wu H-T. et al. Serum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease. Diabetes Manag 2014; 4: 255-261 DOI: 10.2217/dmt.14.17.
• 16 Wu H-T, Ou H-Y, Hung H-C. et al. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia 2016; 59: 1732-1742 DOI: 10.1007/s00125-016-3991-7.
• 17 Huang R, Li C, Du Y. et al. Discovery of a role of the novel hepatokine, hepassocin, in obesity. BioFactors 2020; 46: 100-105 DOI: 10.1002/biof.1574.
• 18 International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676-682 DOI: 10.2337/dc09-1848.
• 19 Gao M, Zhan Y-Q, Yu M. et al. Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway. Cell Signal 2014; 26: 2161-2166 DOI: 10.1016/j.cellsig.2014.04.013.
• 20 Roskoski R.. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res 2012; 66: 105-143 DOI: 10.1016/j.phrs.2012.04.005.
• 21 Jiao P, Feng B, Li Y. et al. Hepatic ERK activity plays a role in energy metabolism. Mol Cell Endocrinol 2013; 375: 157-166 DOI: 10.1016/j.mce.2013.05.021.
• 22 Ou H-Y, Wu H-T, Lin C-H. et al. The hepatic protection effects of hepassocin in hyperglycemic crisis. J Clin Endocrinol Metab 2017; 102: 2407-2415 DOI: 10.1210/jc.2016-3287.
• 23 Ketenci Gencer F, Yuksel S, Goksever Celik H.. Do serum hepassocin levels change in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2021; 267: 137-141 DOI: 10.1016/j.ejogrb.2021.10.034.